Latest News

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

April 11th 2025

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

April 1st 2025

Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo / image credit ©Tefi/stock.adobe.com
Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo

April 1st 2025

 Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

March 31st 2025

Women's  Heart Health News: 5 Studies from ACC.25 / image credit  ©Hamza/stock.adobe.com
Women's Heart Health: 5 Studies from ACC.25

March 28th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.